Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.50
Ask: 14.00
Change: -0.25 (-1.79%)
Spread: 0.50 (3.704%)
Open: 14.00
High: 14.00
Low: 13.75
Prev. Close: 14.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Re US Venture -- Aberro

17 Nov 2005 07:02

Angle PLC17 November 2005 For Immediate Release 17 November 2005 ANGLE PLC US VENTURE, ABERRO: PRODUCT IN BETA TRIALS ANGLE is delighted to announce that it has officially launched Aberro, asoftware testing company (formerly known as ContraSoft). Aberro is 57 per cent.owned by ANGLE and is ANGLE's first US venture founded since ANGLE's flotationin 2004. Aberro has developed a beta release of its product, AberroTest, which is in useat several companies. The product solves a number of issues in the softwareindustry and is expected to be released commercially later this year. Aberro ispreviewing the technology at STARWEST, the world's largest software testingevent, which is being held this week in Anaheim, California. A recent IDC report projected that in 2006, companies will spend over $1 billionon tools to help improve their software testing capabilities. Aberro's AdaptiveAutomated Testing delivers easy and rapid test creation, with no programmingskills required, coupled with low-cost execution that automatically adapts tochanges in the target application. With Aberro's technology, tests areautomatically created in a matter of minutes. This allows testers to find andrepair defects sooner and more easily, while reducing development costs andimproving overall software quality. In developing Aberro, ANGLE has assembled an experienced management team headedby CEO Douglas Smith and Vice President of Marketing Steve Lafferty. Smithjoined the company from ANGLE, where he served as an Entrepreneur in Residence.He has over 20 years of management experience, including CEO and COO roles atthree start-up companies and senior management positions at Digital Equipment,Compaq and EMC. Lafferty previously served as Business Unit Director withManugistics and has held senior-level marketing roles at Cadre, Iona, SterlingSoftware and Green Hills Software. Additionally, Aberro's Co-Founder and CTO William Rogers, Ph.D., brings over 20years of research and development experience to the team. Rogers was theoriginator of Aberro's revolutionary software testing technique, AdaptiveAutomated Testing, which enables rigorous automated testing of software farearlier than any other solution on the market. Rob Kornblum, Managing Director of ANGLE Ventures (US) said: "We are delighted with our progress at Aberro in delivering product to betausers so rapidly. We already see a tremendous amount of interest in Aberro'sproducts from the software community." For more information: ANGLE plc 01483 295830 Andrew Newland, Group CEO Buchanan Communications 020 7466 5000 Richard Darby, Suzanne Brocks, James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE is listed on AIM (AGL.L)and operates from offices in the UK, the US and the Middle East. Further information can be found on www.ANGLEplc.com For more information on Aberro, please visit www.aberrosoftware.com or contactSteve Lafferty at 240.715 3333 x208. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Dec 20157:00 amRNSCompletion of Geomerics Transaction
15th Dec 20157:00 amRNSParsortix first commercial sales
10th Dec 20157:00 amRNSChange of FTSE Industry Classification Benchmark
30th Nov 20155:56 pmRNSHolding(s) in Company
17th Nov 20157:00 amRNSLung Cancer Research Publication
12th Nov 20152:17 pmRNSISSUE OF SHARE OPTIONS
14th Oct 20157:00 amRNSPatent Grant
30th Sep 20155:50 pmRNSResult of AGM
28th Sep 20157:00 amRNSOvarian cancer results
24th Sep 20157:00 amRNSProstrate cancer study published PLOS ONE Journal
9th Sep 20157:00 amRNSBREAST CANCER RESULTS PRESENTED AT CDX CONFERENCE
8th Sep 20153:54 pmRNSAnnual Report and Accounts and Notice of AGM
26th Aug 20151:48 pmRNSIssue of Equity and Total Voting Rights
23rd Jul 20157:00 amRNSFinal Results
20th Jul 20157:00 amRNSNotification of Preliminary Results
8th Jul 20157:00 amRNSAppointment Of Scientific Adviser
11th Jun 20157:00 amRNSBarts Prostate Cancer Update
3rd Jun 20157:00 amRNSAppointment of Scientific Adviser
26th May 20157:01 amRNSNew Patent Grants
21st Apr 20157:00 amRNSOvarian Cancer Update
20th Apr 20157:00 amRNSSidney Kimmel Cancer Centre
14th Apr 20157:00 amRNSIssue of Equity
4th Mar 20157:00 amRNSOffer to Shareholders
25th Feb 20151:11 pmRNSIssue of Equity
20th Feb 20154:05 pmRNSHolding(s) in Company
16th Feb 20157:01 amRNSMD Anderson Collaboration
16th Feb 20157:00 amRNSPlacing, Subscription and Offer
29th Jan 20157:00 amRNSInterim Results
27th Jan 20157:01 amRNS"Unprecedented Specificity" in Ovarian Cancer
23rd Jan 20157:00 amRNSCorporate Collaboration
23rd Jan 20157:00 amRNSPointMan collaboration with ANGLE plc
21st Jan 20153:00 pmRNSFurther information re Director's share transfer
19th Jan 20157:00 amRNSNotification of Interim Results
8th Jan 20157:00 amRNSCorporate Collaboration
15th Dec 20147:00 amRNSCancer Research Manchester Institute Publication
12th Nov 20147:00 amRNSFurther information re Director's share transfer
10th Nov 20147:00 amRNSIssue of Share Options
31st Oct 20147:00 amRNSADR PROGRAMME
21st Oct 20147:00 amRNSDirector's Share Transfer
17th Oct 20147:00 amRNSCollaboration with Barts Cancer Institute
17th Oct 20147:00 amRNSKey Opinion Leaders Report on Parsortix System
30th Sep 20144:30 pmRNSResult of AGM
30th Sep 20147:00 amRNSCollaboration with Thomas Jefferson University
25th Sep 20147:00 amRNSADR Programme, FDA Update and US Appointment
19th Sep 20147:00 amRNSBreast Cancer Collaboration
17th Sep 20147:00 amRNSCollaboration with Medical University of Vienna
8th Sep 20147:00 amRNSHamburg-Eppendorf Collaboration
4th Aug 20147:00 amRNSParsortix Granted Second US Patent
23rd Jul 20147:00 amRNSPreliminary Results
22nd Jul 20147:00 amRNSParsortix Evaluation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.